Healthy AdultNCT07800156
The Effect of Aerobic Exercise on the Irisin/Klotho/Sirtuin-1/BDNF Axis
A study testing Aerobic exercise in people with Healthy Adult and Athlete, run by Cemre Didem Eyipinar at 1 site in Turkey (Türkiye).
Trial summary
The purpose of this study is to investigate the effects of an acute aerobic exercise on irisin, klotho, sirtuin-1, and BDNF levels in the healthy adults. The findings will help understand the physiological impacts of exercise on these biomarkers. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult, Athlete
- What is being tested?
- Aerobic exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Sep 2026to 2 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Being between the ages of 18 and 45
- Being in good health and having no diagnosis of any chronic disease
- Not having taken regular medication within the last 4 weeks
- Voluntary participation and providing written informed consent
Who cannot join
- Individuals with a history of cardiovascular, endocrine, metabolic, or renal disease
- Individuals with a history of active infection, musculoskeletal injury, or severe disability
- Individuals with any medical condition that might prevent participation in exercise
- Individuals unable to regularly participate in the exercise protocol throughout the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Gaziantep University Faculty of Sports Sciences
Gaziantep, Sehitkamil, 85142
CEMRE, 05452645486, cemreeyipinar@gantep.edu.tr
About this study
Official title: The Effect of Aerobic Exercise on the Irisin/Klotho/Sirtuin-1/BDNF Axis: A Randomized Controlled Study
The purpose of this study is to investigate the effects of an acute aerobic exercise on irisin, klotho, sirtuin-1, and BDNF levels in the healthy adults. The findings will help understand the physiological impacts of exercise on these biomarkers.
- Conditions
- Healthy Adult, Athlete
- Being tested
- Aerobic exercise
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aerobic exerciseBehavioural
Acute aerobic exercise until exhaustion
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group | Experimental | Aerobic exercise Receives: Behavioral: Aerobic exercise |
| Control Group | No intervention | No exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary Irisin Level
Irisin concentration will be determined from a saliva sample using the ELISA technique.
Measured: Baseline- immediately after exercise and 1 hours after exercise
Salivary Klotho Level
Klotho concentration will be determined from a saliva sample using the ELISA technique.
Measured: Baseline- immediately after exercise and 1 hours after exercise
Salivary Sirtuin Level
Sirtuin concentration will be determined from a saliva sample using the ELISA technique.
Measured: Baseline- immediately after exercise and 1 hours after exercise
Salivary BDNF Level
BDNF concentration will be determined from a saliva sample using the ELISA technique.
Measured: Baseline- immediately after exercise and 1 hours after exercise
Secondary outcomes (1)
Saliva Flow Rate
It will be calculated individually by dividing the weight of the saliva collected within one minute by the duration.
Measured: Baseline- İmmediately after exercise and 1 hour after exercise
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start2 Sep 2026 (estimated)
- Primary completion2 Apr 2027 (estimated)
- Study completion2 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cemre Didem Eyipinar
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Cemre Didem Eyipinar, University of Gaziantep
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07800156
- Sponsor's protocol ID
- KAEK-120
- Status last verified
- Aug 2026
- First submitted
- 28 Aug 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Aerobic Exercise on the Irisin/Klotho/Sirtuin-1/BDNF Axis: A Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT07800156
- Acronym / sponsor ID
- KAEK-120
- Conditions
- Healthy Adult, Athlete
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- Cemre Didem EyipinarUniversity, hospital or other
- Study start
- 2 Sep 2026 (estimated)
- Primary completion
- 2 Apr 2027 (estimated)
- Study completion
- 2 May 2027 (estimated)
- First posted
- 2 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the effects of an acute aerobic exercise on irisin, klotho, sirtuin-1, and BDNF levels in the healthy adults. The findings will help understand the physiological impacts of exercise on these biomarkers.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group | Experimental | Behavioral: Aerobic exerciseAerobic exercise |
| Control Group | No intervention | –No exercise |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Being between the ages of 18 and 45
- Being in good health and having no diagnosis of any chronic disease
- Not having taken regular medication within the last 4 weeks
- Voluntary participation and providing written informed consent
Key exclusion criteria (4 listed)
- Individuals with a history of cardiovascular, endocrine, metabolic, or renal disease
- Individuals with a history of active infection, musculoskeletal injury, or severe disability
- Individuals with any medical condition that might prevent participation in exercise
- Individuals unable to regularly participate in the exercise protocol throughout the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aerobic exerciseAcute aerobic exercise until exhaustion | Behavioural | Experimental Group |
Primary outcome
Salivary Irisin Level
Time frame: Baseline- immediately after exercise and 1 hours after exercise
Irisin concentration will be determined from a saliva sample using the ELISA technique.
Salivary Klotho Level
Time frame: Baseline- immediately after exercise and 1 hours after exercise
Klotho concentration will be determined from a saliva sample using the ELISA technique.
Salivary Sirtuin Level
Time frame: Baseline- immediately after exercise and 1 hours after exercise
Sirtuin concentration will be determined from a saliva sample using the ELISA technique.
Salivary BDNF Level
Time frame: Baseline- immediately after exercise and 1 hours after exercise
BDNF concentration will be determined from a saliva sample using the ELISA technique.
1 secondary outcome
Saliva Flow Rate
Time frame: Baseline- İmmediately after exercise and 1 hour after exercise
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Adult
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aerobic exercise in people with Healthy Adult and Athlete, run by Cemre Didem Eyipinar at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cemre Didem Eyipınar, PhD (+90 545 264 54 86, cemreeyipinar@gantep.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary Irisin Level (time frame: Baseline- immediately after exercise and 1 hours after exercise). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.